MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略

Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is...

Descripción completa

Detalles Bibliográficos
Autores principales: LI, Shuzhan, ZHANG, Xinwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600752/
https://www.ncbi.nlm.nih.gov/pubmed/37985154
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.33
_version_ 1785126053774098432
author LI, Shuzhan
ZHANG, Xinwei
author_facet LI, Shuzhan
ZHANG, Xinwei
author_sort LI, Shuzhan
collection PubMed
description Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance.
format Online
Article
Text
id pubmed-10600752
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-106007522023-10-27 MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略 LI, Shuzhan ZHANG, Xinwei Zhongguo Fei Ai Za Zhi Review Mesenchymal to epithelial transition factor (MET) gene alterations involve in the proliferation, invasion, and metastasis of non-small cell lung cancer. MET-tyrosine kinase inhibitors (TKIs) have been approved to treat non-small cell lung cancer with MET alterations, and resistance to these TKIs is inevitable. Molecular mechanisms of resistance to MET-TKIs are completely unclear. The review focused on potential mechanisms of MET-TKIs resistance and therapeutics strategies to delay and prevent resistance. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600752/ /pubmed/37985154 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.33 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Review
LI, Shuzhan
ZHANG, Xinwei
MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title_full MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title_fullStr MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title_full_unstemmed MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title_short MET基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
title_sort met基因改变的非小细胞肺癌靶向治疗耐药机制及治疗策略
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600752/
https://www.ncbi.nlm.nih.gov/pubmed/37985154
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.102.33
work_keys_str_mv AT lishuzhan metjīyīngǎibiàndefēixiǎoxìbāofèiáibǎxiàngzhìliáonàiyàojīzhìjízhìliáocèlüè
AT zhangxinwei metjīyīngǎibiàndefēixiǎoxìbāofèiáibǎxiàngzhìliáonàiyàojīzhìjízhìliáocèlüè

Ejemplares similares